Saturday, 31 October 2026European Markets

PARAGON ID Stock Over 34% Up In The Last 21 Sessions

Loading stream...

(vianews) - shares of paragon id (cac 40: pid.pa) rose by a staggering 34.07% in 21 sessions from €28 to €37.54 at 14:06 est on thursday, following the last session's upward trend. cac 40 is rising 0.79% to €7,391.02, after four consecutive sessions in a row of gains.

paragon id's last close was €37.53, 0.19% below its 52-week high of €37.60.

about paragon id

paragon id sa provides identification solutions worldwide. it offers access control, brand protection, contactless ticketing, label, customer relationship management, magnetic and mobile ticketing, near field communication, operation maintenance, rfid technology, secure application module, smartcard kiosk, stock management, timed use ticketing, transport item tracking, and secure service solutions. the company also provides contactless and dual interface smart cards, identification documents, metal bank cards, passport e-covers, rfid labels, and etrust that transforms secure paper-based products into intelligent documents, as well as various terminals, including couplers, readers, and accessories. it serves various clients in automotive, aviation, gaming, health, higher education, logistics, luxury products, manufacturing, mass transit and transport, mobility, parking, payment, pharmaceutical, retail, secure id, and sport and leisure industries. the company was incorporated in 2019 and is headquartered in mougins, france. paragon id sa is a subsidiary of paragon group limited.

earnings per share

as for profitability, paragon id has a trailing twelve months eps of €-0.06.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -0.42%.

volume

today's last reported volume for paragon id is 62 which is 95.68% below its average volume of 742.

more news about paragon id (pid.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com